Vimarsana
Biggest News Aggregation in the World

Anil Singhal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anil Singhal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anil Singhal Today - Breaking & Trending Today

NetScout Systems, Inc. (NASDAQ:NTCT) Q3 2024 Earnings Call Transcript - Vimarsana News

NetScout Systems, Inc. (NASDAQ:NTCT) Q3 2024 Earnings Call Transcript

NetScout Systems, Inc. (NASDAQ:NTCT) Q3 2024 Earnings Call Transcript January 25, 2024 NetScout Systems, Inc. beats earnings expectations. Reported EPS is $0.73, expectations were $0.38. NetScout Systems, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for […]

Source: yahoo.com
NetScout Systems, Inc. (NASDAQ:NTCT) Q3 2024 Earnings Call Transcript - Vimarsana News

NetScout Systems, Inc. (NASDAQ:NTCT) Q3 2024 Earnings Call Transcript

NetScout Systems, Inc. beats earnings expectations. Reported EPS is $0.73, expectations were $0.38.

NETSCOUT Reports Third Quarter Fiscal Year 2024 Financial Results - Vimarsana News

NETSCOUT Reports Third Quarter Fiscal Year 2024 Financial Results

NETSCOUT SYSTEMS, INC. , a leading provider of performance management, cybersecurity, and DDoS attack protection solutions, today announced financial results for its third quarter ended December 31,...

NIT Srinagar commemorates Constitution Day - Vimarsana News

NIT Srinagar commemorates Constitution Day

Srinagar: The National Institute of Technology (NIT) Srinagar observed Constitution Day on Sunday, coinciding with the Janjatiya Gaurav Diwas Celebrations, in adherence to the directive from the Department of Higher Education, Ministry of Education, Government of India. Dr. Kurella Swamy, the Nodal Officer for Janjatiya Gaurav Diwas Celebrations at NIT Srinagar, orchestrated the event under the guidance of the esteemed Director,

Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients - Vimarsana News

Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients

/PRNewswire/ -- Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today announced the initiation of a randomized Phase 2...